Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
MYL's Cash-to-Debt is ranked lower than
95% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MYL: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 4.21 Max: 49.83
Current: 0.05
0.02
49.83
Equity-to-Asset 0.36
MYL's Equity-to-Asset is ranked lower than
84% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 0.94
Current: 0.36
0.19
0.94
Debt-to-Equity 1.17
MYL's Debt-to-Equity is ranked lower than
87% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. MYL: 1.17 )
Ranked among companies with meaningful Debt-to-Equity only.
MYL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.04 Max: 2.73
Current: 1.17
0.01
2.73
Debt-to-EBITDA 5.74
MYL's Debt-to-EBITDA is ranked lower than
82% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. MYL: 5.74 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.22  Med: 4.72 Max: 7.4
Current: 5.74
3.22
7.4
Interest Coverage 1.56
MYL's Interest Coverage is ranked lower than
93% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. MYL: 1.56 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.29 Max: 8.18
Current: 1.56
0.83
8.18
Piotroski F-Score: 4
Altman Z-Score: 1.23
Beneish M-Score: -2.53
WACC vs ROIC
10.19%
4.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 7.38
MYL's Operating Margin % is ranked lower than
52% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MYL: 7.38 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 5.8  Med: 15.91 Max: 26.53
Current: 7.38
5.8
26.53
Net Margin % 5.51
MYL's Net Margin % is ranked lower than
53% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. MYL: 5.51 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 8.88 Max: 13.48
Current: 5.51
-3.53
13.48
ROE % 5.72
MYL's ROE % is ranked lower than
54% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. MYL: 5.72 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 14.08 Max: 29.99
Current: 5.72
-14.72
29.99
ROA % 1.95
MYL's ROA % is ranked lower than
59% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MYL: 1.95 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 4.52 Max: 7.1
Current: 1.95
-2.47
7.1
ROC (Joel Greenblatt) % 20.17
MYL's ROC (Joel Greenblatt) % is ranked higher than
62% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. MYL: 20.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.32  Med: 28.81 Max: 47.2
Current: 20.17
14.32
47.2
3-Year Revenue Growth Rate 6.70
MYL's 3-Year Revenue Growth Rate is ranked higher than
55% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYL: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 6.7
-6.1
54.5
3-Year EBITDA Growth Rate 0.30
MYL's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. MYL: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.4  Med: 11.1 Max: 107.9
Current: 0.3
-20.4
107.9
3-Year EPS without NRI Growth Rate -16.50
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MYL: -16.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: 8.1 Max: 110.4
Current: -16.5
-29.1
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 30-Y Financials

Financials (Next Earnings Date: 2017-11-06)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

MYL Guru Trades in Q4 2016

David Tepper 3,275,000 sh (New)
Jim Simons 1,504,000 sh (New)
First Pacific Advisors 3,085,731 sh (New)
Lee Ainslie 3,799,281 sh (+184.28%)
David Einhorn 8,670,307 sh (+35.47%)
Vanguard Health Care Fund 30,084,537 sh (+3.21%)
Mario Gabelli 16,512 sh (+3.12%)
John Paulson 904,200 sh (unchged)
Joel Greenblatt Sold Out
Scott Black 40,841 sh (-0.81%)
Pioneer Investments 54,144 sh (-1.27%)
John Paulson 20,602,500 sh (-5.54%)
Paul Tudor Jones 5,500 sh (-49.54%)
» More
Q1 2017

MYL Guru Trades in Q1 2017

Joel Greenblatt 648,342 sh (New)
Richard Pzena 7,262,316 sh (New)
Steven Cohen 3,602,271 sh (New)
Paul Tudor Jones 99,063 sh (+1701.15%)
First Pacific Advisors 5,349,600 sh (+73.37%)
Jim Simons 2,488,400 sh (+65.45%)
David Einhorn 8,692,307 sh (+0.25%)
John Paulson 200,000 sh (unchged)
Steven Cohen 40,000 sh (unchged)
Scott Black 40,821 sh (-0.05%)
Vanguard Health Care Fund 29,295,842 sh (-2.62%)
Mario Gabelli 14,500 sh (-12.19%)
John Paulson 17,274,387 sh (-16.15%)
Pioneer Investments 35,014 sh (-35.33%)
David Tepper 1,900,000 sh (-41.98%)
Lee Ainslie 1,545,448 sh (-59.32%)
» More
Q2 2017

MYL Guru Trades in Q2 2017

Steven Romick 6,341,690 sh (New)
Richard Pzena 12,339,687 sh (+69.91%)
First Pacific Advisors 8,187,380 sh (+53.05%)
Joel Greenblatt 833,660 sh (+28.58%)
David Einhorn 10,701,707 sh (+23.12%)
Mario Gabelli 14,501 sh (+0.01%)
Vanguard Health Care Fund 29,295,842 sh (unchged)
Pioneer Investments 35,014 sh (unchged)
John Paulson 200,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
David Tepper Sold Out
Lee Ainslie Sold Out
Scott Black Sold Out
John Paulson 15,933,600 sh (-7.76%)
Steven Cohen 802,548 sh (-77.72%)
» More
Q3 2017

MYL Guru Trades in Q3 2017

Diamond Hill Capital 15,980 sh (New)
Steven Romick 7,425,690 sh (+17.09%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Reduce -7.76%0.7%$36.72 - $40.09 $ 38.470%15,933,600
Richard Pzena 2017-06-30 Add 69.91%1.08%$36.72 - $40.09 $ 38.470%12,339,687
David Einhorn 2017-06-30 Add 23.12%1.26%$36.72 - $40.09 $ 38.470%10,701,707
Joel Greenblatt 2017-06-30 Add 28.58%0.1%$36.72 - $40.09 $ 38.470%833,660
Mario Gabelli 2017-06-30 Add 0.01%$36.72 - $40.09 $ 38.470%14,501
David Tepper 2017-06-30 Sold Out 1.22%$36.72 - $40.09 $ 38.470%0
Vanguard Health Care Fund 2017-03-31 Reduce -2.62%0.07%$35.81 - $45.28 $ 38.47-5%29,295,842
John Paulson 2017-03-31 Reduce -16.15%1.62%$35.81 - $45.28 $ 38.47-5%17,274,387
David Einhorn 2017-03-31 Add 0.25%0.01%$35.81 - $45.28 $ 38.47-5%8,692,307
Richard Pzena 2017-03-31 New Buy1.6%$35.81 - $45.28 $ 38.47-5%7,262,316
David Tepper 2017-03-31 Reduce -41.98%0.93%$35.81 - $45.28 $ 38.47-5%1,900,000
Joel Greenblatt 2017-03-31 New Buy0.32%$35.81 - $45.28 $ 38.47-5%648,342
Mario Gabelli 2017-03-31 Reduce -12.19%$35.81 - $45.28 $ 38.47-5%14,500
Vanguard Health Care Fund 2016-12-31 Add 3.21%0.09%$34.14 - $38.92 $ 38.474%30,084,537
John Paulson 2016-12-31 Reduce -5.54%0.51%$34.14 - $38.92 $ 38.474%20,602,500
David Einhorn 2016-12-31 Add 35.47%1.49%$34.14 - $38.92 $ 38.474%8,670,307
David Tepper 2016-12-31 New Buy2.22%$34.14 - $38.92 $ 38.474%3,275,000
Mario Gabelli 2016-12-31 Add 3.12%$34.14 - $38.92 $ 38.474%16,512
Joel Greenblatt 2016-12-31 Sold Out 0.01%$34.14 - $38.92 $ 38.474%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:4507, NYSE:TEVA, NSE:SUNPHARMA, SHSE:600518, TSE:4523, SZSE:000538, TSE:4508, NYSE:PRGO, SHSE:600196, OCSE:LUN, XPAR:IPN, JSE:APN, IST:DEVA, SHSE:600276, BOM:532321, HKSE:03320, XSWX:VIFN, SZSE:000963, SHSE:603858, BOM:500257 » details
Traded in other countries:MYL.Austria, 6MY.Germany, MYL.Israel, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is the world's third-largest generic pharmaceutical manufacturer with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales comprise approximately 84% of revenue. Remaining sales come from a handful of branded products, primarily the epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Top Ranked Articles about Mylan NV

Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017
Mylan Invalidates Allergan's Patents on Restasis®
Mylan Receives CRL for Neulasta Biosimilar Company's co-developer partner has to provide FDA with more data
Mylan NV (NASDAQ:MYL) – the U.K.-headquartered health care company that is engaged in the development, production and global distribution of generic, brand name and over-the-counter products – has received from the Food and Drug Administration (FDA) a Complete Response Letter (or CRL) with reference to its U.S. marketing application for its MYL-1401H, as reported by its co-developer partner Biocon Ltd. (NSE:BIOCON). Read more...
Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL
Mylan Launches First AP-rated Generic Avelox® Injection
Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily
Mylan Rises on FDA Approval of Generic MS Drug Teva falls as Copaxone now has competition
The S&P 500, Nasdaq and Dow Jones opened lower on Wednesday after registering record highs the past several days, but soon reversed. Read more...
Mylan Provides Support for U.S. Disaster-Relief Efforts
Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
Mylan Launches Generic Cancidas® for Injection

Ratios

vs
industry
vs
history
PE Ratio 31.05
MYL's PE Ratio is ranked higher than
50% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. MYL: 31.05 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 26.56 Max: 112.56
Current: 31.05
7.32
112.56
Forward PE Ratio 7.20
MYL's Forward PE Ratio is ranked higher than
92% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. MYL: 7.20 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.05
MYL's PE Ratio without NRI is ranked higher than
51% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. MYL: 31.05 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 26.56 Max: 112.56
Current: 31.05
7.32
112.56
Price-to-Owner-Earnings 33.46
MYL's Price-to-Owner-Earnings is ranked higher than
60% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. MYL: 33.46 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.37  Med: 34.12 Max: 310
Current: 33.46
13.37
310
PB Ratio 1.60
MYL's PB Ratio is ranked higher than
81% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MYL: 1.60 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.43 Max: 7.02
Current: 1.6
0.64
7.02
PS Ratio 1.69
MYL's PS Ratio is ranked higher than
74% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MYL: 1.69 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.72 Max: 3.94
Current: 1.69
0.4
3.94
Price-to-Free-Cash-Flow 13.24
MYL's Price-to-Free-Cash-Flow is ranked higher than
83% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. MYL: 13.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 19.89 Max: 115.12
Current: 13.24
8.82
115.12
Price-to-Operating-Cash-Flow 7.93
MYL's Price-to-Operating-Cash-Flow is ranked higher than
88% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. MYL: 7.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.73 Max: 40.9
Current: 7.93
6.07
40.9
EV-to-EBIT 40.35
MYL's EV-to-EBIT is ranked lower than
78% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. MYL: 40.35 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.6  Med: 19.6 Max: 74.5
Current: 40.35
-10.6
74.5
EV-to-EBITDA 13.28
MYL's EV-to-EBITDA is ranked higher than
68% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. MYL: 13.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.5 Max: 23.3
Current: 13.28
-17.7
23.3
EV-to-Revenue 2.89
MYL's EV-to-Revenue is ranked higher than
56% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. MYL: 2.89 )
Ranked among companies with meaningful EV-to-Revenue only.
MYL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 2.7 Max: 5.6
Current: 2.89
1.5
5.6
PEG Ratio 7.40
MYL's PEG Ratio is ranked lower than
83% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. MYL: 7.40 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.85 Max: 13.61
Current: 7.4
0.72
13.61
Shiller PE Ratio 85.40
MYL's Shiller PE Ratio is ranked lower than
74% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. MYL: 85.40 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 83.45 Max: 173.66
Current: 85.4
14.48
173.66
Current Ratio 1.35
MYL's Current Ratio is ranked lower than
77% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. MYL: 1.35 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.7 Max: 11.71
Current: 1.35
0.83
11.71
Quick Ratio 0.84
MYL's Quick Ratio is ranked lower than
84% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. MYL: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.49 Max: 8.47
Current: 0.84
0.55
8.47
Days Inventory 128.85
MYL's Days Inventory is ranked lower than
55% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. MYL: 128.85 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 133.92 Max: 168.24
Current: 128.85
88.95
168.24
Days Sales Outstanding 80.34
MYL's Days Sales Outstanding is ranked lower than
56% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. MYL: 80.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 86.72 Max: 107.26
Current: 80.34
77.49
107.26
Days Payable 37.79
MYL's Days Payable is ranked lower than
79% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. MYL: 37.79 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 37.79  Med: 70.84 Max: 101.21
Current: 37.79
37.79
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. MYL: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -1 Max: 7.4
Current: -12.9
-25.8
7.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.08
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. MYL: 1.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.57 Max: 5.33
Current: 1.08
0.62
5.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.90
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
73% of the 85 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. MYL: 2.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MYL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 1.76 Max: 7.86
Current: 2.9
0.46
7.86
Price-to-Median-PS-Value 0.99
MYL's Price-to-Median-PS-Value is ranked higher than
72% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. MYL: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 2.24 Max: 8.34
Current: 0.99
0.38
8.34
Earnings Yield (Greenblatt) % 2.48
MYL's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. MYL: 2.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.7  Med: 4.6 Max: 19
Current: 2.48
-15.7
19
Forward Rate of Return (Yacktman) % 8.62
MYL's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. MYL: 8.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 13.2 Max: 24.9
Current: 8.62
7.8
24.9

More Statistics

Revenue (TTM) (Mil) $12,006.60
EPS (TTM) $ 1.24
Beta1.54
Short Percentage of Float5.99%
52-Week Range $29.39 - 45.87
Shares Outstanding (Mil)536.28

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 12,096 12,549 13,077 13,383
EPS ($) 4.60 5.33 5.79 5.78
EPS without NRI ($) 4.60 5.33 5.79 5.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.23%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}